Metastasis of breast cancer to bones alters the tumor immune microenvironment

Table 1 Patient characteristics

Variable	N	%
Bone metastasis lesions	63
Primary tumor and matched bone metastasis	31	49.21
Primary tumor histology
Ductal, non-special type	51	80.95
Ductal, micropapillary	1	1.59
Ductal, mucinous	2	3.17
Ductal and lobular	2	3.17
Uncertain	7	11.11
Primary tumor grade
1	1	1.59
2	15	23.81
3	40	63.49
Uncertain	7	11.11
Primary tumor phenotypes
Luminal A	11	17.46
Luminal B	29	46.03
HER2 amplification	15	23.81
Triple-negative	4	6.35
Uncertain	4	6.35
Primary tumor size
< 2 cm	11	17.46
2–5 cm	24	38.10
> 5 cm	2	3.17
Uncertain	26	41.27
Nodes status
Negative	10	15.87
1–3 nodes	20	31.75
4–9 nodes	4	6.35
> 10	13	20.63
Uncertain	16	25.40
Surgery
Mastectomy	44	69.84
Breast conserving surgery	5	7.94
None	5	7.94
Uncertain	9	14.29
Chemotherapy
Adjuvant	54	85.71
Neoadjuvant	1	1.59
None	8	12.70
Radiotherapy
Adjuvant	26	41.27
None	37	58.73
Trastuzumab/pertuzumab application in HER2-positive patients	7/15
Endocrine therapy
Yes	40	63.49
No	23	36.51
Bone metastasis at first diagnosis	5	7.94
Bone metastasis sites
Ilium	5	7.94
Sternum	7	11.11
Rib	1	1.59
Vertebra	43	68.25
Femur	3	4.76
Humerus	1	1.59
Skull	1	1.59
Treatment after bone metastasis
Radiotherapy	8	12.70
Chemotherapy	27	42.86
Endocrine therapy	42	66.67
Trastuzumab/pertuzumab	4	6.35
Alive at last follow-up	43	68.25

ISSN: 2047-783X